Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and the reimbursement status of these drugs; to assess the relationship between the type of recommendation and reimbursement status. Methods: The list of orphan drugs to be included in the analysis was obtained from the European Medicines Agency and Orphanet. Seven European states were included in the analysis: Belgium, England, France, Germany, Poland, Scotland, and Spain. For all identified orphan drugs, relevant data on the reimbursement status and type of recommendation were collected for each country. The relationship between the type of recommendation and reimbursement status was evaluated separatel...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
What is known and Objective: Variations in market uptake of an orphan drug have important implicatio...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
Objective: To review the reimbursement recommendations issued by selected European health technology...
Background: Reimbursement policies influence access of patients to orphan drugs in the European coun...
Background The aim of this study was to review and compare types of reimbursement recommendations fo...
Objective: To assess shares of reimbursed orphan drugs and agreement in reimbursement decision-makin...
BACKGROUND: The reimbursement of orphan drugs (OD) is an increasingly important for country policyma...
A409BACKGROUND: Orphan medicinal products are designed to diagnose or treat rare diseases that are ...
BackgroundReimbursement policies influence access of patients to orphan drugs in the European countr...
OBJECTIVES: In the Netherlands, orphan drug developers can be exempted from providing a full phwhere...
BACKGROUND: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
BACKGROUND: This paper analyses schemes to promote the authorisation of and reimbursement for orphan...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
What is known and Objective: Variations in market uptake of an orphan drug have important implicatio...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...
Objective: To review the reimbursement recommendations issued by selected European health technology...
Background: Reimbursement policies influence access of patients to orphan drugs in the European coun...
Background The aim of this study was to review and compare types of reimbursement recommendations fo...
Objective: To assess shares of reimbursed orphan drugs and agreement in reimbursement decision-makin...
BACKGROUND: The reimbursement of orphan drugs (OD) is an increasingly important for country policyma...
A409BACKGROUND: Orphan medicinal products are designed to diagnose or treat rare diseases that are ...
BackgroundReimbursement policies influence access of patients to orphan drugs in the European countr...
OBJECTIVES: In the Netherlands, orphan drug developers can be exempted from providing a full phwhere...
BACKGROUND: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
BACKGROUND: This paper analyses schemes to promote the authorisation of and reimbursement for orphan...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
Background: Pharmacoeconomic evaluations of new drug therapies are often required for reimbursement ...
What is known and Objective: Variations in market uptake of an orphan drug have important implicatio...
p. 343-350An orphan disease is a disease with a very low prevalence. Although there are 5000-7000 or...